In the current study, we demonstrated that the increased CXCR4 expression in trastuzumab-resistant tumor cells is associated with cell cycle progression and reaches a peak in the G2/M phases, contributing to cell proliferation and survival. Here, CXCR4 is linked to neoplasm.